. , , , (. 1).
1.
(%) | |||
(%) | 10 | ||
+ 10 | |||
+ 20 | |||
+ 20 | |||
25 | |||
( ) | 33 | ||
25 | |||
( ) | 33 |
(conversion ratios), (. 2).
2. , | ||
(%) | ||
A% | ||
, , , | T% | T/A x 100 |
, , , | R% | R/T x 100 |
:
( . , , ) | |
(, : , , ) | |
( ). |
:
, , . | |
, , , |
.
.
|
|
, .
, , , , , . 50% . , , , , .
, , , , , (. 3). 10% . , ( , , , ).
3. | ||
% | (%) | |
60% | ||
30% | 50% | |
3% | 10% |
GRP (gross rating point) , , (. 4). , . GRP, [1].
4. (01.01.1999 19.09.1999) | ||||||
, | , USD* | GRPs | Eq.Q.C.P.R., $ | |||
SmithKline Beecham | Coldrex | 109 207 | 325,15 | 370,65 | ||
SmithKline Beecham | Bactroban | 51 479 | 713,20 | 216,64 | ||
SmithKline Beecham | 160 686 | 264,86 | ||||
Bristol-Myers Squibb company | Fervex | 120 760 | 574,16 | 259,66 | ||
Bristol-Myers Squibb company | Efferalgan | 35 756 | 245,35 | 300,49 | ||
Bristol-Myers Squibb company | 156 516 | 819,51 | 271,89 | |||
Johnson &Jonson | Tylenol | 143 026 | 784,97 | 250,80 | ||
Johnson &Jonson | Nizoral | 90 128 | 799,11 | 225,57 | ||
Johnson &Jonson | Motilium | 50 325 | 452,56 | 222,40 | ||
Johnson &Jonson | 283 479 | 2036,64 | 234,59 |
* .
, : . : . 1999. 37
Eq.C.P.R. (equal cost per rating point), , GRP. , , GRP, Eq.C.P.R. . Eq.C.P.R. , . . .
|
|
( ) , - (., ), , . , , , . AGB Ukraine.